Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News; $RARE Ultragenyx Pharmaceutical Inc (RARE) Q3 2020 Earnings Call Transcript
Image source: The Motley Fool. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Q3 2020 Earnings Call Oct 27, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Ultragenyx Pharmaceutical Inc (RARE) Q3 2020 Earnings Call Tr...
Read the whole news RARE - Ultragenyx Pharmaceutical Inc (RARE) Q3 2020 Earnings Call Transcript
News: $RARE Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma
NOVATO, Calif. and NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Royalty Pharma today announced that Ultragenyx has sold to R...
Read the whole news RARE - Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma
News: $RARE Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer
NOVATO, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced it has promoted Erik Harris to Executive Vice President...
In case you are interested https://marketwirenews.com/news-releases/ultragenyx-expands-leadership-team-and-promotes-erik-harris-to-chief-commercial-officer-8368310.html
What does this Miss Primary end points mean for $RARE?
https://finance.yahoo.com/news/ultragenyx-announces-negative-topline-results-120000119.html
$RARE - FDA approves treatment for rare genetic enzyme disorder
https://www.fda.gov:80/FDAgov/NewsEvents/Newsroom/PressAnnouncements/ucm585308.htm
Congrats to those who got in! Still a long way to run. 100 by EOY.
https://biotechinvesting.info/2016/08/05/ultragenyx/
Here's a more detailed bull case for $RARE
https://biotechinvesting.info/2016/08/05/bull-case-for-ultragenyx-rare/
RARE - Top biotech stock for the money right now: https://biotechinvesting.info/2016/07/22/sold-tgtx-bought-more-rare/
$RARE recent news/filings
bullish 100.28
falling wedge breakout
bullish engulfing candle
## source: finance.yahoo.com
Sat, 05 Dec 2015 18:17:33 GMT ~ Is Ultragenyx Pharmaceutical Inc (RARE) Going to Burn These Hedge Funds?
read full: http://www.insidermonkey.com/blog/is-ultragenyx-pharmaceutical-inc-rare-going-to-burn-these-hedge-funds-397331/
*********************************************************
Thu, 03 Dec 2015 13:30:00 GMT ~ Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of KRN23 in Adults With X-Linked Hypophosphatemia (XLH)
[GlobeNewswire] - NOVATO, Calif., Dec. 03, 2015-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the initiation ...
read full: http://finance.yahoo.com/news/ultragenyx-announces-first-patient-enrolled-133000975.html
*********************************************************
Wed, 02 Dec 2015 21:30:00 GMT ~ Ultragenyx to Present at the Oppenheimer Annual Healthcare Conference
[GlobeNewswire] - NOVATO, Calif., Dec. 02, 2015-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, ...
read full: http://finance.yahoo.com/news/ultragenyx-present-oppenheimer-annual-healthcare-213000446.html
*********************************************************
Wed, 02 Dec 2015 13:30:00 GMT ~ Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia
[GlobeNewswire] - NOVATO, Calif., Dec. 02, 2015-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim ...
read full: http://finance.yahoo.com/news/ultragenyx-reports-positive-interim-40-133000458.html
*********************************************************
Wed, 18 Nov 2015 18:04:24 GMT ~ ULTRAGENYX PHARMACEUTICAL INC. Financials
read full: http://finance.yahoo.com/q/is?s=rare
*********************************************************
$RARE charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$RARE company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/RARE/company-info
Ticker: $RARE
OTC Market Place: Not Available
CIK code: not found
Company name: Ultragenyx Pharmaceutical Inc.
Incorporated In:
$RARE share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$RARE extra dd links
Company name: Ultragenyx Pharmaceutical Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RARE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RARE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RARE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RARE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RARE+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/news - http://finance.yahoo.com/q/h?s=RARE+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RARE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RARE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RARE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RARE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RARE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RARE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ultragenyx+Pharmaceutical+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ultragenyx+Pharmaceutical+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ultragenyx+Pharmaceutical+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RARE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RARE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RARE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RARE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RARE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RARE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RARE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RARE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RARE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RARE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RARE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RARE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RARE+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RARE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RARE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RARE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RARE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RARE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RARE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RARE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RARE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RARE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RARE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RARE
$RARE DD Notes ~ http://www.ddnotesmaker.com/RARE
$RARE recent news/filings
bullish optionable
bull flag breakout
## source: finance.yahoo.com
Tue, 01 Sep 2015 13:29:00 GMT ~ 9:29 am Ultragenyx Pharma announces the presentation of open-label data from five infants with cardiomyopathy due to long-chain fatty acid oxidation disorders treated with triheptanoin
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#rare
*********************************************************
Tue, 01 Sep 2015 13:23:03 GMT ~ Ultragenyx Announces Presentation of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin
[at noodls] - NOVATO, Calif., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
read full: http://www.noodls.com/view/CDCD3CE5C6961F414106227884A3B7A5A1BD6EFB
*********************************************************
Tue, 01 Sep 2015 13:00:00 GMT ~ Ultragenyx Announces Presentation of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin
[GlobeNewswire] - NOVATO, Calif. -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation ...
read full: http://finance.yahoo.com/news/ultragenyx-announces-presentation-data-long-130000477.html
*********************************************************
Tue, 01 Sep 2015 10:14:52 GMT ~ Coverage initiated on Ultragenyx Pharma by Raymond James
read full: http://finance.yahoo.com/q/ud?s=RARE
*********************************************************
Sat, 22 Aug 2015 17:04:11 GMT ~ ULTRAGENYX PHARMACEUTICAL INC. Financials
read full: http://finance.yahoo.com/q/is?s=rare
*********************************************************
$RARE charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$RARE company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/RARE/company-info
Ticker: $RARE
OTC Market Place: Not Available
CIK code: not found
Company name: Ultragenyx Pharmaceutical Inc.
Incorporated In:
Business Description: OTC Markets | Official site of the OTCQX, OTCQB and OTC Pink Marketplaces featuring Free Stock & Bond Quotes, Trade Prices, Chart, Financials and Company News & Information for Investors, Companies and Traders - OTCMarkets.com (window.NREUM||(NREUM={})).loader_config={xpid:"UwMGWVdSGwQIU1RQAgQ="};window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o?o:e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;od;d++)c[d].apply(u,n);return u}function a(t,e){f[t]=s(t).concat(e)}function s(t){return f[t]||[]}function c(){return n(e)}var f={};return{on:a,emit:e,create:c,listeners:s,_events:f}}function r(){return{}}var o="nr@context",i=t("gos");e.exports=n()},{gos:"7eSDFh"}],ee:[function(t,e){e.exports=t("QJf3ax")},{}],3:[function(t){function e(t){try{i.console&&console.log(t)}catch(e){}}var n,r=t("ee"),o=t(1),i={};try{n=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(i.console=!0,-1!==n.indexOf("dev")&&(i.dev=!0),-1!==n.indexOf("nr_dev")&&(i.nrDev=!0))}catch(a){}i.nrDev&&r.on("internal-error",function(t){e(t.stack)}),i.dev&&r.on("fn-err",function(t,n,r){e(r.stack)}),i.dev&&(e("NR AGENT IN DEVELOPMENT MODE"),e("flags: "+o(i,function(t){return t}).join(", ")))},{1:23,ee:"QJf3ax"}],4:[function(t){function e(t,e,n,i,s){try{c?c-=1:r("err",[s||new UncaughtException(t,e,n)])}catch(f){try{r("ierr",[f,(new Date).getTime(),!0])}catch(u){}}return"function"==typeof a?a.apply(this,o(arguments)):!1}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function n(t){r("err",[t,(new Date).getTime()])}var r=t("handle"),o=t(6),i=t("ee"),a=window.onerror,s=!1,c=0;t("loader").features.err=!0,t(5),window.onerror=e;try{throw new Error}catch(f){"stack"in f&&(t(1),t(2),"addEventListener"in window&&t(3),window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)&&t(4),s=!0)}i.on("fn-start",function(){s&&(c+=1)}),i.on("fn-err",function(t,e,r){s&&(this.thrown=!0,n(r))}),i.on("fn-end",function(){s&&!this.thrown&&c>0&&(c-=1)}),i.on("internal-error",function(t){r("ierr",[t,(new Date).getTime(),!0])})},{1:10,2:9,3:7,4:11,5:3,6:24,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],5:[function(t){t("loader").features.ins=!0},{loader:"G9z0Bl"}],6:[function(t){function e(){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var n=t("ee"),r=t("handle"),o=t(1),i=t(2);t("loader").features.stn=!0,t(3),n.on("fn-start",function(t){var e=t[0];e instanceof Event&&(this.bstStart=Date.now())}),n.on("fn-end",function(t,e){var n=t[0];n instanceof Event&&r("bst",[n,e,this.bstStart,Date.now()])}),o.on("fn-start",function(t,e,n){this.bstStart=Date.now(),this.bstType=n}),o.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),this.bstType])}),i.on("fn-start",function(){this.bstStart=Date.now()}),i.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),"requestAnimationFrame"])}),n.on("pushState-start",function(){this.time=Date.now(),this.startPath=location.pathname+location.hash}),n.on("pushState-end",function(){r("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),"addEventListener"in window.performance&&(window.performance.addEventListener("webkitresourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.webkitClearResourceTimings()},!1),window.performance.addEventListener("resourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.clearResourceTimings()},!1)),document.addEventListener("scroll",e,!1),document.addEventListener("keypress",e,!1),document.addEventListener("click",e,!1)}},{1:10,2:9,3:8,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],7:[function(t,e){function n(t){i.inPlace(t,["addEventListener","removeEventListener"],"-",r)}function r(t){return t[1]}var o=t("ee").create(),i=t(1)(o),a=t("gos");if(e.exports=o,n(window),"getPrototypeOf"in Object){for(var s=document;s&&!s.hasOwnProperty("addEventListener");)s=Object.getPrototypeOf(s);s&&n(s);for(var c=XMLHttpRequest.prototype;c&&!c.hasOwnProperty("addEventListener");)c=Object.getPrototypeOf(c);c&&n(c)}else XMLHttpRequest.prototype.hasOwnProperty("addEventListener")&&n(XMLHttpRequest.prototype);o.on("addEventListener-start",function(t){if(t[1]){var e=t[1];"function"==typeof e?this.wrapped=t[1]=a(e,"nr@wrapped",function(){return i(e,"fn-",null,e.name||"anonymous")}):"function"==typeof e.handleEvent&&i.inPlace(e,["handleEvent"],"fn-")}}),o.on("removeEventListener-start",function(t){var e=this.wrapped;e&&(t[1]=e)})},{1:25,ee:"QJf3ax",gos:"7eSDFh"}],8:[function(t,e){var n=t("ee").create(),r=t(1)(n);e.exports=n,r.inPlace(window.history,["pushState"],"-")},{1:25,ee:"QJf3ax"}],9:[function(t,e){var n=t("ee").create(),r=t(1)(n);e.exports=n,r.inPlace(window,["requestAnimationFrame","mozRequestAnimationFrame","webkitRequestAnimationFrame","msRequestAnimationFrame"],"raf-"),n.on("raf-start",function(t){t[0]=r(t[0],"fn-")})},{1:25,ee:"QJf3ax"}],10:[function(t,e){function n(t,e,n){t[0]=o(t[0],"fn-",null,n)}var r=t("ee").create(),o=t(1)(r);e.exports=r,o.inPlace(window,["setTimeout","setInterval","setImmediate"],"setTimer-"),r.on("setTimer-start",n)},{1:25,ee:"QJf3ax"}],11:[function(t,e){function n(){f.inPlace(this,p,"fn-")}function r(t,e){f.inPlace(e,["onreadystatechange"],"fn-")}function o(t,e){return e}function i(t,e){for(var n in t)e[n]=t[n];return e}var a=t("ee").create(),s=t(1),c=t(2),f=c(a),u=c(s),d=window.XMLHttpRequest,p=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"];e.exports=a,window.XMLHttpRequest=function(t){var e=new d(t);try{a.emit("new-xhr",[],e),u.inPlace(e,["addEventListener","removeEventListener"],"-",o),e.addEventListener("readystatechange",n,!1)}catch(r){try{a.emit("internal-error",[r])}catch(i){}}return e},i(d,XMLHttpRequest),XMLHttpRequest.prototype=d.prototype,f.inPlace(XMLHttpRequest.prototype,["open","send"],"-xhr-",o),a.on("send-xhr-start",r),a.on("open-xhr-start",r)},{1:7,2:25,ee:"QJf3ax"}],12:[function(t){function e(t){var e=this.params,r=this.metrics;if(!this.ended){this.ended=!0;for(var i=0;c>i;i++)t.removeEventListener(s,this.listener,!1);if(!e.aborted){if(r.duration=(new Date).getTime()-this.startTime,4===t.readyState){e.status=t.status;var a=t.responseType,f="arraybuffer"===a||"blob"===a||"json"===a?t.response:t.responseText,u=n(f);if(u&&(r.rxSize=u),this.sameOrigin){var d=t.getResponseHeader("X-NewRelic-App-Data");d&&(e.cat=d.split(", ").pop())}}else e.status=0;r.cbTime=this.cbTime,o("xhr",[e,r,this.startTime])}}}function n(t){if("string"==typeof t&&t.length)return t.length;if("object"!=typeof t)return void 0;if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if("undefined"!=typeof FormData&&t instanceof FormData)return void 0;try{return JSON.stringify(t).length}catch(e){return void 0}}function r(t,e){var n=i(e),r=t.params;r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.sameOrigin=n.sameOrigin}if(window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)){t("loader").features.xhr=!0;var o=t("handle"),i=t(2),a=t("ee"),s=["load","error","abort","timeout"],c=s.length,f=t(1);t(4),t(3),a.on("new-xhr",function(){this.totalCbs=0,this.called=0,this.cbTime=0,this.end=e,this.ended=!1,this.xhrGuids={}}),a.on("open-xhr-start",function(t){this.params={method:t[0]},r(this,t[1]),this.metrics={}}),a.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid)}),a.on("send-xhr-start",function(t,e){var r=this.metrics,o=t[0],i=this;if(r&&o){var f=n(o);f&&(r.txSize=f)}this.startTime=(new Date).getTime(),this.listener=function(t){try{"abort"===t.type&&(i.params.aborted=!0),("load"!==t.type||i.called===i.totalCbs&&(i.onloadCalled||"function"!=typeof e.onload))&&i.end(e)}catch(n){try{a.emit("internal-error",[n])}catch(r){}}};for(var u=0;c>u;u++)e.addEventListener(s,this.listener,!1)}),a.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),a.on("xhr-load-added",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),a.on("xhr-load-removed",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),a.on("addEventListener-end",function(t,e){e instanceof XMLHttpRequest&&"load"===t[0]&&a.emit("xhr-load-added",[t[1],t[2]],e)}),a.on("removeEventListener-end",function(t,e){e instanceof XMLHttpRequest&&"load"===t[0]&&a.emit("xhr-load-removed",[t[1],t[2]],e)}),a.on("fn-start",function(t,e,n){e instanceof XMLHttpRequest&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=(new Date).getTime()))}),a.on("fn-end",function(t,e){this.xhrCbStart&&a.emit("xhr-cb-time",[(new Date).getTime()-this.xhrCbStart,this.onload,e],e)})}},{1:"XL7HBI",2:13,3:11,4:7,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],13:[function(t,e){e.exports=function(t){var e=document.createElement("a"),n=window.location,r={};e.href=t,r.port=e.port;var o=e.href.split("://");return!r.port&&o[1]&&(r.port=o[1].split("/")[0].split("@").pop().split(":")[1]),r.port&&"0"!==r.port||(r.port="https"===o[0]?"443":"80"),r.hostname=e.hostname||n.hostname,r.pathname=e.pathname,r.protocol=o[0],"/"!==r.pathname.charAt(0)&&(r.pathname="/"+r.pathname),r.sameOrigin=!e.hostname||e.hostname===document.domain&&e.port===n.port&&e.protocol===n.protocol,r}},{}],14:[function(t,e){function n(t){return function(){r(t,[(new Date).getTime()].concat(i(arguments)))}}var r=t("handle"),o=t(1),i=t(2);"undefined"==typeof window.newrelic&&(newrelic=window.NREUM);var a=["setPageViewName","addPageAction","setCustomAttribute","finished","addToTrace","inlineHit","noticeError"];o(a,function(t,e){window.NREUM[e]=n("api-"+e)}),e.exports=window.NREUM},{1:23,2:24,handle:"D5DuLP"}],gos:[function(t,e){e.exports=t("7eSDFh")},{}],"7eSDFh":[function(t,e){function n(t,e,n){if(r.call(t,e))return t[e];var o=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return t[e]=o,o}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],D5DuLP:[function(t,e){function n(t,e,n){return r.listeners(t).length?r.emit(t,e,n):void(r.q&&(r.q[t]||(r.q[t]=[]),r.q[t].push(e)))}var r=t("ee").create();e.exports=n,n.ee=r,r.q={}},{ee:"QJf3ax"}],handle:[function(t,e){e.exports=t("D5DuLP")},{}],XL7HBI:[function(t,e){function n(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:i(t,o,function(){return r++})}var r=1,o="nr@id",i=t("gos");e.exports=n},{gos:"7eSDFh"}],id:[function(t,e){e.exports=t("XL7HBI")},{}],G9z0Bl:[function(t,e){function n(){var t=p.info=NREUM.info,e=f.getElementsByTagName("script")[0];if(t&&t.licenseKey&&t.applicationID&&e){s(d,function(e,n){e in t||(t[e]=n)});var n="https"===u.split(":")[0]||t.sslForHttp;p.proto=n?"https://":"http://",a("mark",["onload",i()]);var r=f.createElement("script");r.src=p.proto+t.agent,e.parentNode.insertBefore(r,e)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=t("handle"),s=t(1),c=window,f=c.document;t(2);var u=(""+location).split("?")[0],d={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-686.min.js"},p=e.exports={offset:i(),origin:u,features:{}};f.addEventListener?(f.addEventListener("DOMContentLoaded",o,!1),c.addEventListener("load",n,!1)):(f.attachEvent("onreadystatechange",r),c.attachEvent("onload",n)),a("mark",["firstbyte",i()])},{1:23,2:14,handle:"D5DuLP"}],loader:[function(t,e){e.exports=t("G9z0Bl")},{}],23:[function(t,e){function n(t,e){var n=[],o="",i=0;for(o in t)r.call(t,o)&&(n=e(o,t[o]),i+=1);return n}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],24:[function(t,e){function n(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(0>o?0:o);++r
$RARE share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$RARE extra dd links
Company name: Ultragenyx Pharmaceutical Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RARE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RARE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RARE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RARE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RARE+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/news - http://finance.yahoo.com/q/h?s=RARE+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RARE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RARE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RARE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RARE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RARE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RARE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ultragenyx+Pharmaceutical+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ultragenyx+Pharmaceutical+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ultragenyx+Pharmaceutical+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RARE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RARE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RARE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RARE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RARE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RARE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RARE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RARE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RARE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RARE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RARE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RARE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RARE+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RARE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RARE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RARE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RARE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RARE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RARE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RARE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RARE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RARE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RARE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RARE
$RARE DD Notes ~ http://www.ddnotesmaker.com/RARE
$RARE recent news/filings
bullish
higher highs, higher lows uptrend
unusually strong green CMF indicator, people are definitely buying
climbing acc/dist line
good volume
pharmaceutical index gapping up strong bullish, stocks follow the index
## source: finance.yahoo.com
Fri, 10 Jul 2015 16:42:45 GMT ~ Story Stocks from Briefing.com
[Briefing.com] - Story Stocks from Briefing.com
read full: http://finance.yahoo.com/news/story-stocks-briefing-com-112019114.html
*********************************************************
Thu, 09 Jul 2015 13:09:13 GMT ~ Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia
[at noodls] - NOVATO, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
read full: http://www.noodls.com/view/889E805479FA8AE62C572F0F3A8432243E350652
*********************************************************
Thu, 09 Jul 2015 13:01:00 GMT ~ 9:01 am Ultragenyx Pharma announced positive interim data in the ongoing pediatric Phase 2 study for recombinant human monoclonal antibody KRN23
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#rare
*********************************************************
Thu, 09 Jul 2015 13:00:00 GMT ~ Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia
[GlobeNewswire] - NOVATO, Calif. -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim ...
read full: http://finance.yahoo.com/news/ultragenyx-releases-positive-interim-40-130000004.html
*********************************************************
Thu, 09 Jul 2015 10:58:16 GMT ~ Coverage initiated on Ultragenyx Pharma by JMP Securities
read full: http://finance.yahoo.com/q/ud?s=RARE
*********************************************************
$RARE charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$RARE company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/RARE/company-info
Ticker: $RARE
OTC Market Place: Not Available
CIK code: not found
Company name: Ultragenyx Pharmaceutical Inc.
Incorporated In:
$RARE share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$RARE extra dd links
Company name: Ultragenyx Pharmaceutical Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RARE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RARE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RARE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RARE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RARE+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/news - http://finance.yahoo.com/q/h?s=RARE+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RARE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RARE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RARE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RARE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RARE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RARE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ultragenyx+Pharmaceutical+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ultragenyx+Pharmaceutical+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ultragenyx+Pharmaceutical+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RARE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RARE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RARE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RARE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RARE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RARE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RARE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RARE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RARE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RARE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RARE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RARE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RARE+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RARE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RARE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RARE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RARE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RARE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RARE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RARE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RARE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RARE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RARE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RARE
$RARE DD Notes ~ http://www.ddnotesmaker.com/RARE
$RARE recent news/filings
bullish
## source: finance.yahoo.com
Mon, 08 Jun 2015 13:17:02 GMT ~ Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7
[at noodls] - NOVATO, Calif., June 8, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
read full: http://www.noodls.com/view/6C3658995B817A651D2EC2AE11B355A918994EF6
*********************************************************
Mon, 08 Jun 2015 13:00:00 GMT ~ Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7
[GlobeNewswire] - NOVATO, Calif. -- Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced it has completed patient enrollment ...
read full: http://finance.yahoo.com/news/ultragenyx-announces-completion-enrollment-phase-130000501.html
*********************************************************
Thu, 04 Jun 2015 13:31:11 GMT ~ Ultragenyx Appoints Dennis Huang as Chief Technical Operations Officer and Senior Vice President
[at noodls] - NOVATO, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
read full: http://www.noodls.com/view/F3860C2675B8ADEE791EB0BC3C0FE3CA94026752
*********************************************************
Thu, 04 Jun 2015 13:00:00 GMT ~ Ultragenyx Appoints Dennis Huang as Chief Technical Operations Officer and Senior Vice President
[GlobeNewswire] - NOVATO, Calif. -- Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced it has appointed Dennis Huang ...
read full: http://finance.yahoo.com/news/ultragenyx-appoints-dennis-huang-chief-130000146.html
*********************************************************
Wed, 03 Jun 2015 19:00:07 GMT ~ Ultragenyx KRN23 Positive in Children, to be Studied in Adults - Analyst Blog
read full: http://finance.yahoo.com/news/ultragenyx-krn23-positive-children-studied-190007809.html
*********************************************************
$RARE charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$RARE company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/RARE/company-info
Ticker: $RARE
OTC Market Place: Not Available
CIK code: not found
Company name: Ultragenyx Pharmaceutical Inc.
Incorporated In:
$RARE share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$RARE extra dd links
Company name: Ultragenyx Pharmaceutical Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RARE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RARE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RARE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RARE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RARE+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/news - http://finance.yahoo.com/q/h?s=RARE+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RARE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RARE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RARE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RARE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RARE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RARE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ultragenyx+Pharmaceutical+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ultragenyx+Pharmaceutical+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ultragenyx+Pharmaceutical+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RARE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RARE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RARE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RARE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RARE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RARE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RARE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RARE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RARE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RARE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RARE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RARE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RARE+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RARE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RARE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RARE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RARE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RARE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RARE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RARE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RARE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RARE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RARE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RARE
$RARE DD Notes ~ http://www.ddnotesmaker.com/RARE
$RARE Top performing IPO in 2014
http://ditrli.com/smart-investing-2014-ipo-winners/
$RARE Cowen Sees Ultragenyx Shares Outperforming Following Phase 1/2 Data http://www.smarteranalyst.com/2014/09/16/cowen-sees-ultragenyx-shares-outperforming-following-phase-12-data/
Ultragenyx Pharmaceutical Inc. [$RARE] due diligence
bullish 120% gain or more on margin
perhaps an inverted head and shoulders pattern forming
http://stockcharts.com/school/doku.php?st=head+and+shoulders&id=chart_school:chart_analysis:chart_patterns:head_and_shoulders_bottom_reversal
hidden bullish macd divergence since June
http://www.tradingsetupsreview.com/macd-hidden-divergence-trading-strategy/
$RARE
DD Notes ~ http://www.ddnotesmaker.com/RARE
##### recent news/filings ~ source: finance.yahoo.com
Wed, 09 Jul 2014 10:52:19 GMT ~ Ultragenyx Pharmaceutical Slumps: RARE Plunges 11.7% in Session
read full: http://finance.yahoo.com/news/ultragenyx-pharmaceutical-slumps-rare-plunges-105219468.html
*********************************************************
Wed, 09 Jul 2014 10:16:06 GMT ~ Ultragenyx Announces Pricing of Public Offering of Common Stock
[at noodls] - NOVATO, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
read full: http://www.noodls.com/view/9FFE8CBF956DB796051313BCC01A85BC64120648
*********************************************************
Wed, 09 Jul 2014 05:00:00 GMT ~ Ultragenyx Announces Pricing of Public Offering of Common Stock
[GlobeNewswire] - NOVATO, Calif. -- Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its underwritten ...
read full: http://finance.yahoo.com/news/ultragenyx-announces-pricing-public-offering-050000787.html
*********************************************************
Tue, 08 Jul 2014 18:10:38 GMT ~ Why Ultragenyx Pharmaceutical Inc. Stock Slumped
read full: http://www.fool.com/investing/general/2014/07/08/why-ultragenyx-pharmaceutical-inc-stock-slumped.aspx?source=eogyholnk0000001
*********************************************************
Mon, 07 Jul 2014 20:41:47 GMT ~ Ultragenyx Announces Proposed Public Offering of Common Stock
[at noodls] - NOVATO, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
read full: http://www.noodls.com/view/C0A7B5AFC8509CEBEF230D67C95F9CEC8E0806B3
*********************************************************
##### chart ~ source: stockcharts.com
##### chart ~ source: eoddata.com
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/RARE/company-info
Ticker: $RARE
OTC Market Place: Not Available
CIK code: not found
Company name: Ultragenyx Pharmaceutical Inc.
Incorporated In:
##### extra dd links
Latest filings: http://www.otcmarkets.com/stock/RARE/filings
Latest financials: http://www.otcmarkets.com/stock/RARE/financials
Latest news: http://www.otcmarkets.com/stock/RARE/news - http://finance.yahoo.com/q/h?s=RARE+Headlines
Major holdings: http://data.cnbc.com/quotes/RARE/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=RARE+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/RARE.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=RARE
RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=RARE&search=search
DTCC: http://search2.dtcc.com/?q=Ultragenyx+Pharmaceutical+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Ultragenyx+Pharmaceutical+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Ultragenyx+Pharmaceutical+Inc.&x=0&y=0
Short Sales: http://www.otcmarkets.com/stock/RARE/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/RARE/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/RARE/research
Historical Prices: http://finance.yahoo.com/q/hp?s=RARE+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=RARE+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=RARE+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=RARE+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=RARE+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=RARE+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=RARE
Balance Sheet: http://finance.yahoo.com/q/bs?s=RARE
Cash Flow: http://finance.yahoo.com/q/cf?s=RARE+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/RARE
Bloomberg: http://www.bloomberg.com/quote/RARE:US
Morningstar: http://quotes.morningstar.com/stock/s?t=RARE
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RARE
Barchart: http://www.barchart.com/quotes/stocks/RARE
OTC Short Report: http://otcshortreport.com/index.php?index=RARE
Investopedia: http://www.investopedia.com/markets/stocks/RARE/?wa=0
http://www.pennystocktweets.com/stocks/profile/RARE
##### last known share structure ~ source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
##### business description ~ source: otcmarkets.com
DD Notes ~ http://www.ddnotesmaker.com/RARE
a11k
Presentation is at 4:00 PM. Today.
4:00
Joyce E Fox
Steven and Alexandra Cohen Children?s Medical Center
New York, NY, United States
Recombinant Human beta-glucuronidase enzyme replacement therapy for mucopolysaccharidosis type VII: report of the first patient treated.
Maybe a surge in PPS tomorrow when attendees invest in RARE
Low Float with plenty of up side.
Just nuts. Slated to issue at $17 per share. Instead issues at $21, then doubles?
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
23
|
Created
|
01/31/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |